Welcome to our dedicated page for Relmada Therapeutics SEC filings (Ticker: RLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Relmada Therapeutics, Inc. uses SEC filings to document its clinical-stage biotechnology business, Nasdaq-listed common stock, governance, operating results, and capital structure. Its Form 8-K filings cover financial results, Regulation FD presentations, FDA feedback and NDV-01 clinical or regulatory disclosures, material agreements, executive employment arrangements, and equity financing activity.
Proxy filings address board matters, executive compensation, shareholder voting items, and related governance disclosures. Capital-structure records include common stock and pre-funded warrant disclosures associated with financing transactions.
Relmada Therapeutics, Inc. (RLMD) filed a Form 4 disclosing a new equity award to director John Glasspool. On 06/26/2025, Glasspool received 100,000 non-qualified stock options with an exercise price of $0.67 per share. The options vest in 16 equal quarterly installments starting 09/26/2025 and expire on 06/26/2035. No common shares were bought or sold; the only reported transaction is the option grant, leaving Glasspool with 100,000 derivative securities held directly. The filing indicates normal onboarding compensation and modest potential dilution relative to RLMD’s outstanding share count (not provided in the document). Investors should view the grant as routine governance practice that aligns the new director’s incentives with long-term shareholder value without any immediate cash outlay or ownership change.